Inovio Shares Plunge 22% After FDA Review Classification for INO-3107

Inovio shares fell 22% to $1.80 after the FDA accepted its Biologics License Application for INO-3107 for review as a potential treatment for recurrent respiratory papillomatosis. However, the FDA has no plans to discuss the application and has assigned a review goal date of Oct. 30, 2026. The FDA also indicated it may not hold an advisory committee meeting to discuss the application. Inovio plans to request a meeting with the FDA to discuss next steps under the accelerated approval pathway.